Liver Cancer

>

Latest News

Immunotherapy-Based Regimens Are Associated With OS Advantage in HCC
Immunotherapy-Based Regimens Are Associated With OS Advantage in HCC

September 20th 2023

Immuno-oncology regimens were linked with improved long-term survival among patients with hepatocellular carcinoma.

liver cancer
Phase 3 Findings Show PFS Benefit With Frontline Rivoceranib Plus Camrelizumab in Patients With Unresectable HCC

July 29th 2023

liver cancer
Adjuvant Atezolizumab/Bevacizumab Shows Recurrence-Free Survival Benefit Over Active Surveillance in HCC

April 17th 2023

HCC
Newer Therapies Outperform Sorafenib in Real-World Analysis of Patients With HCC

February 4th 2023

liver
Adding Pembrolizumab to Lenvatinib Yields Similar HRQOL Scores As Lenvatinib Alone in HCC

January 20th 2023

More News

© 2023 MJH Life Sciences

All rights reserved.